§ 02 — Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇪🇬Egypt	🇺🇸United States
Authority & dossier
Regulatory authority	EDA	FDA
English submissions	Yes	Yes
CTD accepted	Yes	Yes
eCTD accepted	Yes	Yes
Reliance pathway	Available	None
Reference agencies	FDA (US), EMA, MHRA (UK), Health Canada +4	—
Lead pathway (timeline & fees) — New Drug Registration — Standard Review · New Drug Application — 505(b)(1)
Pathway name	New Drug Registration — Standard Review	New Drug Application — 505(b)(1)
Approval timeline	365–730 days	304–365 days
Application fee	EGP 100,000	USD 4,310,002
Annual renewal	EGP 0	USD 416,734
Local representative	Required	Not required
Local manufacturing	Not required	Not required
GMP inspection	Required	Required
MAH & local presence
Local entity required	Yes	No
Local responsible person	Yes	Yes
RP role	MAHs must designate a Qualified Person responsible for the licensed premises (typically a registered pharmacist), and a Qualified Person for Pharmacovigilance (QPPV) as the contact for the Egyptian Pharmacovigilance Centre (EPVC) within EDA.	US Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.
Accelerated pathways
Designations available	3 designations	6 designations
Examples	Reliance / Verification — Expedited Pathway, Emergency Use Authorisation (EUA), Conditional Registration / Compassionate Use Programme	Priority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3
Post-approval lifecycle
Variations framework	Variations are classified per EDA variation guidelines (aligned with EU variation classification) into Type IA / IAIN (notification), Type IB (minor — prior approval), Type II (major — prior approval) and Extensions. EDA aligned its variations framework with EU practice as part of its ML3 work.	FDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.
Renewal cycle	Drug Registration Certificate is initially valid for 10 years (from 2019 reform, replacing the prior 5-year cycle) and renewable for 10 years; renewal requires up-to-date CMC, safety, GMP and labelling information.	FDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.
Pharmacovigilance	The Egyptian Pharmacovigilance Centre (EPVC) within EDA coordinates national ADR reporting; Egypt is a member of the WHO Programme for International Drug Monitoring (Uppsala Monitoring Centre). MAHs must submit PSURs aligned to ICH E2C(R2), report serious ADRs within statutory timelines, and maintain a Risk Management Plan (RMP) for new active substances and vaccines.	Mandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Not permitted	Not permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	60–120 days	30–30 days
GCP standard	ICH E6(R2) GCP; Egyptian Clinical Trials Law No. 214/2020 and EDA GCP guidelines; Helsinki Declaration	ICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56
Pricing & reimbursement
Price regulation	Regulated	Free pricing
Reference pricing	Yes	No
HTA required	No	No
HTA body	No formal national HTA agency; HTA capacity is being developed within EDA and the General Authority for Healthcare Accreditation and Regulation (GAHAR) under the UHI reforms.	ICER (Institute for Clinical and Economic Review) — independent, non-binding

Verdict colours indicate lower, moderate, or higher regulatory burden — they're not value judgements on a market.

Authority & dossier

Regulatory authority

EgyptEDA
United StatesFDA

English submissions

EgyptYes
United StatesYes

CTD accepted

EgyptYes
United StatesYes

eCTD accepted

EgyptYes
United StatesYes

Reliance pathway

EgyptAvailable
United StatesNone

Reference agencies

EgyptFDA (US), EMA, MHRA (UK), Health Canada +4
United States—

Lead pathway (timeline & fees) — New Drug Registration — Standard Review · New Drug Application — 505(b)(1)

Pathway name

EgyptNew Drug Registration — Standard Review
United StatesNew Drug Application — 505(b)(1)

Approval timeline

Egypt365–730 days
United States304–365 days

Application fee

EgyptEGP 100,000
United StatesUSD 4,310,002

Annual renewal

EgyptEGP 0
United StatesUSD 416,734

Local representative

EgyptRequired
United StatesNot required

Local manufacturing

EgyptNot required
United StatesNot required

GMP inspection

EgyptRequired
United StatesRequired

MAH & local presence

Local entity required

EgyptYes
United StatesNo

Local responsible person

EgyptYes
United StatesYes

RP role

EgyptMAHs must designate a Qualified Person responsible for the licensed premises (typically a registered pharmacist), and a Qualified Person for Pharmacovigilance (QPPV) as the contact for the Egyptian Pharmacovigilance Centre (EPVC) within EDA.
United StatesUS Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.

Accelerated pathways

Designations available

Egypt3 designations
United States6 designations

Examples

EgyptReliance / Verification — Expedited Pathway, Emergency Use Authorisation (EUA), Conditional Registration / Compassionate Use Programme
United StatesPriority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3

Post-approval lifecycle

Variations framework

EgyptVariations are classified per EDA variation guidelines (aligned with EU variation classification) into Type IA / IAIN (notification), Type IB (minor — prior approval), Type II (major — prior approval) and Extensions. EDA aligned its variations framework with EU practice as part of its ML3 work.
United StatesFDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.

Renewal cycle

EgyptDrug Registration Certificate is initially valid for 10 years (from 2019 reform, replacing the prior 5-year cycle) and renewable for 10 years; renewal requires up-to-date CMC, safety, GMP and labelling information.
United StatesFDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.

Pharmacovigilance

EgyptThe Egyptian Pharmacovigilance Centre (EPVC) within EDA coordinates national ADR reporting; Egypt is a member of the WHO Programme for International Drug Monitoring (Uppsala Monitoring Centre). MAHs must submit PSURs aligned to ICH E2C(R2), report serious ADRs within statutory timelines, and maintain a Risk Management Plan (RMP) for new active substances and vaccines.
United StatesMandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.

Unlicensed access

Named Patient Supply

EgyptAvailable
United StatesAvailable

Compassionate Use

EgyptAvailable
United StatesAvailable

Emergency Import

EgyptAvailable
United StatesAvailable

Parallel Import

EgyptNot permitted
United StatesNot permitted

Clinical trials

CTA approval

EgyptRequired
United StatesRequired

Ethics approval

EgyptYes
United StatesYes

CTA timeline

Egypt60–120 days
United States30–30 days

GCP standard

EgyptICH E6(R2) GCP; Egyptian Clinical Trials Law No. 214/2020 and EDA GCP guidelines; Helsinki Declaration
United StatesICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56

Pricing & reimbursement

Price regulation

EgyptRegulated
United StatesFree pricing

Reference pricing

EgyptYes
United StatesNo

HTA required

EgyptNo
United StatesNo

HTA body

EgyptNo formal national HTA agency; HTA capacity is being developed within EDA and the General Authority for Healthcare Accreditation and Regulation (GAHAR) under the UHI reforms.
United StatesICER (Institute for Clinical and Economic Review) — independent, non-binding